




Baseline Characteristics

	INTERMITTENT (N=60)	CONTINUOUS (N=58)	COMPARATOR (N=60)	Overall (N=178)
Age, median (range), years	60 (38, 81)	60 (45, 75)	61.5 (41, 81)	61 (38, 81)
Refractory**, no. (%)	23 (38.3%)	20 (34.5%)	22 (36.7%)	65 (36.5%)
Primary refractory, no (%)	7 (11.7%)	3 (5.2%)	1 (1.7%)	11 (6.2%)
Number of prior therapies, median (range)	2.5 (1, 4)	3 (1, 5)	3 (1, 4)	3 (1, 5)
Lines of prior chemotherapy, median (range)	2(1, 4)	2(1, 5)*	2(1, 4)	2(1, 5)
Prior cancer therapy, no. (%)				
Bevacizumab	31 (51.7%)	37 (63.8%)	37 (61.7%)	105 (59.0%)
PARP	18 (30.0%)	27 (46.6%)	20 (33.3%)	65 (36.5%)
Molecular profiling (available in a subset of the study population only)				
BRCA1(+), n/N (%)	5/43 (11.6%)	4/43 (9.3%)	7/49 (14.3%)	16/135 (11.9%)
BRCA2(+), n/N (%)	1/37 (2.7%)	3/39 (7.7%)	3/39 (7.7%)	7/115 (6.1%)

* 1 patient with bevacizumab counted as a separate line
** progressing during or within 1 month from last platinum treatment
CONTINUOUS, once-daily relacorilant + nab-paclitaxel; INTERMITTENT, intermittent relacorilant + nab-paclitaxel;
COMPARATOR, nab-paclitaxel monotherapy

FIG. 2

Patient Disposition


	INTERMITTENT (N=60)	CONTINUOUS (N=58)	COMPARATOR (N=60)	Overall (N=178)
Safety population	60	57	60	177
Discontinuation of study drug ^a , no. (%)	53 (88.3%)	54 (93.1%)	56 (93.3%)	163 (91.6%)
Disease progression	40 (66.7%)	40 (69.0%)	47 (78.3%)	127 (71.3%)
Adverse event	7 (11.7%)	9 (13.8%)	4 (6.7%)	20 (11.2%)
Death	1 (1.7%)	2 (3.4%)*	2 (3.3%)	5 (2.8%)
Other	5 (8.3%)	3 (5.2%)	3 (5.0%)	11 (6.2%)

^a Discontinuation of either relacorilant or nab-paclitaxel

^b 1 patient discontinued relacorilant and nab-paclitaxel for different reasons (clinical progression and adverse event, respectively) CONTINUOUS, once daily relacorilant + nab-paclitaxel; INTERMITTENT, intermittent relacorilant + nab-paclitaxel; COMPARATOR, nab-paclitaxel monotherapy

FIG. 3

INTERMITTENT Relacorilant + Nab-paclitaxel
Improved Progression-Free Survival






FIG. 4B




FIG. 5




FIG. 6A




FIG. 6B

Efficacy Analysis – data cut-off 22 March 2021

Efficacy Analysis

	INTERMITTENT			CONTINUOUS			COMPARATOR		
	Overall (N=60)	Primary Platinum- Refractory Removed (N=53)	Overall (N=58)	Primary Platinum- Refractory Removed (N=55)	Overall (N=60)	Primary Platinum- Refractory Removed (N=59)			
Progression-free survival^a, median (95% CI), months	5.55, (3.68, 7.20)	5.55, (3.68, 7.29)	5.29, (3.84, 5.55)	5.29, (3.84, 5.55)	3.76, (3.52, 5.36)	3.75, (3.52, 5.36)			
HR vs Comparator, (95% CI)	0.66, (0.44, 0.98)	0.64, (0.42, 0.96)	0.83, (0.56, 1.22)	0.83, (0.56, 1.23)	N/A	N/A			
P-value	0.44	0.03	0.33	0.34	N/A	N/A			
Objective response rate, n (%)	20 (35.7%)	19 (35.8%)	19 (35.2%)	19 (34.5%)	19 (35.8%)	19 (32.2%)			
P-value	0.99	0.69	0.97	0.79	N/A	N/A			
Duration of response^a, median (95% CI), months	5.55 (3.75, 5.88)	5.55 (3.75, 5.88)	3.79 (2.33, 5.55)	3.79, (2.33, 5.55)	3.65 (2.89, 5.09)	3.65 (2.89, 5.09)			
HR vs Comparator, (95% CI)	0.36 (0.16, 0.77)	0.36 (0.16, 0.77)	0.72 (0.33, 1.58)	0.72 (0.33, 1.58)	N/A	N/A			
P-value	0.006	0.006	0.042	0.042	N/A	N/A			
Overall survival^a, median (95% CI), months	12.94, (9.13, --)	12.94, (11.89, --)	11.30, (7.59, --)	11.30, (7.59, --)	10.41, (8.41, 16.76)	10.41, (7.72, 16.76)			
HR vs Comparator, (95% CI)	0.63 (0.35, 1.14)	0.55, (0.29, 1.03)	1.07 (0.62, 1.85)	1.00, (0.57, 1.76)	N/A	N/A			
P-value	0.124	0.056	0.813	0.99	N/A	N/A			

^a Kaplan-Meier estimate
CONTINUOUS, once-daily relacorilant + nab-paclitaxel; INTERMITTENT, intermittent relacorilant + nab-paclitaxel; COMPARATOR, nab-paclitaxel; monotherapy

FIG. 7A

Subgroup: Results from Patients without Primary Platinum-Refractory Disease, who had from 1 to 3 Prior Lines of Therapy

	Intermittent Relacorilant + Nab-paclitaxel (N=46)	Nab-paclitaxel Monotherapy (N=50)
PFS¹		
Number of events, (%)	36 (78.3%)	48 (96.0%)
Median PFS (95% CI), months	5.6 (3.7, 7.3)	3.8 (3.5, 5.4)
HR (95% CI)	0.58 (0.37, 0.91)	—
Log-rank test, <i>P</i> -value ²	0.016	—
DoR¹ in patients with objective response		
Number of patients with objective response	18	17
Number of events (%)	13 (72.2%)	16 (94.1%)
Median DoR (95% CI), months	5.6 (3.8, 5.9)	3.6 (1.9, 3.8)
HR (95% CI)	0.26 (0.11, 0.62)	—
Log-rank test, <i>P</i> -value ²	0.001	—
OS³		
Number of events, (%)	29 (63.0%)	43 (86.0%)
Median OS (95% CI), months	13.9 (11.1, 18.4)	12.2 (7.7, 15.3)
HR (95% CI)	0.52 (0.31, 0.86)	—
Log-rank test, <i>P</i> -value ²	0.01	—

¹Data cutoff date for the primary analysis: March 22, 2021; applies to PFS and DoR.
²*P*-values are nominal, no multiplicity adjustment applied.
³Data cutoff date for the final (OS) analysis: March 7, 2022.

FIG. 7B

Intermittent Relacorilant Administration vs. Comparator
Subgroup: Excludes Primary Platinum-Refractory Patients and
Patients with Greater Than 4 Prior Lines of Therapy

Overall Survival – data cut-off 7 March 2022

Overall Survival in Patients Excluding Primary Refractory and ≥4 Prior Lines




FIG. 7C

Subgroup: Results from Patients without Primary Platinum-Refractory Disease, who had from 1 to 3 Prior Lines of Therapy Which Prior Therapy Included BEVACIZUMAB Therapy

	Intermittent Relacorilant + Nab-paclitaxel (N=25)	Nab-paclitaxel Monotherapy (N=31)
PFS¹		
Number of events, (%)	20 (80.0%)	30 (96.8%)
Median PFS (95% CI), months	7.3 (3.7, 7.7)	3.7 (2.2, 5.3)
HR (95% CI)	0.40 (0.21, 0.77)	—
Log-rank test, <i>P</i> -value ²	0.005	—
DoR¹ in patients with objective response		
Number of patients with objective response	10	9
Number of events (%)	7 (70.0%)	9 (100.0%)
Median DoR (95% CI), months	5.6 (3.7, NR)	3.1 (1.3, NR)
HR (95% CI)	0.29 (0.09, 0.99)	—
Log-rank test, <i>P</i> -value ²	0.016	—
OS³		
Number of events, (%)	15 (60.0%)	25 (80.6%)
Median OS (95% CI), months	17.9 (12.8, NR)	12.6 (6.4, 15.3)
HR (95% CI)	0.38 (0.17, 0.82)	—
Log-rank test, <i>P</i> -value ²	0.011	—

¹Data cutoff date for the primary analysis: March 22, 2021; applies to PFS and DoR.
²*P*-values are nominal, no multiplicity adjustment applied.
³Data cutoff date for the final (OS) analysis: March 7, 2022.
NR, not reached

FIG. 7D

Initial Analysis - data cut-off 22 March 2021


The Safety and Tolerability of Intermittent Relacorilant + Nab-Paclitaxel is Comparable to Nab-Paclitaxel Monotherapy

n, (%)	INTERMITTENT N=60	CONTINUOUS N=57	COMPARATOR N=60	OVERALL N=177
Neutropenia ^a	12 (20.0%)	22 (38.6%)	22 (36.7%)	56 (31.6%)
Grade ≥3	4 (6.7%)	15 (26.3%)	9 (15.0%)	28 (15.8%)
Febrile Neutropenia (Grade 3) ^b	0 (0.0%)	0 (0.0%)	1 (1.7%)	1 (0.01%)
Anemia ^c	29 (48.3)	37 (64.9%)	34 (56.7%)	100 (56.5%)
Grade ≥3	8 (13.3%)	11 (19.3%)	7 (11.7%)	26 (14.7%)
Peripheral neuropathy ^d	21 (35.0%)	27 (47.4%)	18 (30.0%)	66 (37.3%)
Grade ≥3	0 (0.0%)	9 (15.8%)	3 (5.0%)	12 (0.07%)
Fatigue or asthenia	33 (55.0%)	41 (71.9%)	39 (65.0%)	113 (96.6%)
Grade ≥3	6 (10.0%)	5 (8.8%)	1 (1.7%)	12 (0.07%)

^a Neutropenia, neutrophil count decreased; ^b Secondary to E.coli urinary sepsis in this patient; ^c Anemia, hemoglobin decreased; ^d Neuropathy peripheral, neurotoxicity, peripheral motor neuropathy, peripheral sensorimotor neuropathy, peripheral sensory neuropathy CONTINUOUS, once-daily relacorilant + nab-paclitaxel; INTERMITTENT, intermittent relacorilant + nab-paclitaxel; COMPARATOR, nab-paclitaxel monotherapy; G-CSF, granulocyte-colony stimulating factor

- ▶ All relacorilant-treated patients received prophylactic G-CSF per protocol to reduce the risk of neutropenia
- ▶ 46.7% of patients in the comparator arm received G-CSF per the investigator's standard practice

FIG. 8



Response rate in patients with H-score ≥ 100 :

	CR/PR
Relacorilant + nab-paclitaxel	40.4%
Nab-paclitaxel	18.8%

FIG. 9A

15/ 19





FIG. 9B



Arm A: continuous relacorilant+NP
Arm B: intermittent relacorilant+NP
Arm C: NP alone

SGK1: serum and glucocorticoid regulated kinase 1
GSK3B: Glycogen synthase kinase 3 beta
PIK3CG: Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

FIG. 9C




FIG. 9D





FIG. 10A

Planned PHASE 3 Clinical Study Design



BICR, blinded independent central review; INV, investigator; BOR, best overall response.

FIG. 10B